Eli Lilly’s Retatrutide Hits Record Weight Loss, Challenges Surgery Efficacy | Whalesbook
Retatrutide Is Producing Remarkable Weight-Loss Results
The next generation of obesity medicines is moving quickly.
One of the most closely watched candidates is retatrutide for weight loss, an experimental drug being developed by Eli Lilly.
In May 2026, Lilly reported Phase 3 TRIUMPH-1 results showing that participants receiving the highest studied dose lost an average of 28.3% of their body weight after 80 weeks.
That result has placed retatrutide among the most closely watched investigational treatments in obesity research.
But there is an important distinction.
Retatrutide is still an investigational drug and is not FDA-approved for weight loss.
What Is Retatrutide?
Retatrutide is designed to activate three hormone receptors:
- GLP-1
- GIP
- Glucagon
That makes it different from medicines such as semaglutide, which primarily targets GLP-1, and tirzepatide, which targets GLP-1 and GIP.
The three-receptor approach is one reason researchers are studying retatrutide so closely.
The goal is to influence appetite, energy balance and metabolism through several biological pathways at the same time.
What Did the TRIUMPH-1 Trial Find?
The Phase 3 TRIUMPH-1 trial evaluated retatrutide in adults with obesity or overweight plus at least one weight-related health condition, without diabetes.
At 80 weeks, the reported average weight changes were:
| Retatrutide dose | Average weight loss |
| 4 mg | 19.0% |
| 9 mg | 25.9% |
| 12 mg | 28.3% |
| Placebo | 2.2% |
These figures are based on the trial’s efficacy estimand.
The 12 mg group lost an average of about 70.3 pounds.
The results also showed that 45.3% of participants receiving 12 mg achieved at least 30% weight loss at 80 weeks.
What Happened in People With Severe Obesity?
The results were especially notable among participants with a baseline BMI of at least 35 who continued into a pre-specified extension.
At 104 weeks, people receiving retatrutide 12 mg to their maximum tolerated dose achieved an average weight loss of approximately 30.3%, or about 85 pounds.
This is one reason researchers are interested in retatrutide for people with more severe obesity.
However, these results should not be interpreted as a guarantee for an individual patient.
Clinical-trial results describe groups of participants, not what every person will experience.
Retatrutide Also Improved Several Health Measures
Weight was not the only outcome examined.
The TRIUMPH-1 results reported improvements in several cardiometabolic risk measures, including:
- Waist circumference
- Non-HDL cholesterol
- Triglycerides
- Systolic blood pressure
- High-sensitivity C-reactive protein
These changes are relevant because obesity is associated with multiple metabolic and cardiovascular risks.
What Side Effects Were Reported?
Retatrutide produced gastrointestinal side effects similar to those commonly seen with other incretin-based medicines.
Among the reported adverse events were:
- Nausea
- Diarrhea
- Constipation
- Vomiting
At the 12 mg dose, Lilly reported nausea in 42.4% of participants, diarrhea in 32.0%, constipation in 26.1% and vomiting in 25.3%.
Dysesthesia, involving unusual skin sensations, was also reported.
These findings highlight why a drug with impressive weight-loss results still requires careful evaluation of tolerability and long-term safety.
Is Retatrutide FDA Approved?
No.
This is one of the most important points to understand in 2026.
Retatrutide remains an investigational medicine. FDA information states that retatrutide is not an active ingredient in an FDA-approved drug.
That means people should not treat online products marketed as “retatrutide” as equivalent to an FDA-approved prescription treatment.
The FDA has also taken action against companies marketing unapproved retatrutide products.
How Does Retatrutide Compare With Current GLP-1 Medicines?
The most interesting feature of retatrutide is its triple-receptor action.
Semaglutide targets GLP-1.
Tirzepatide targets GLP-1 and GIP.
Retatrutide targets GLP-1, GIP and glucagon.
The early and Phase 3 results suggest that this broader mechanism may produce substantial weight loss.
But direct comparisons between different trials must be made carefully.
A drug should not be declared better simply by comparing percentages from separate studies.
For readers interested in why individual people respond differently to current GLP-1 medicines, our article on who benefits most from Wegovy and Mounjaro provides useful context.
How people respond differently to Wegovy and Mounjaro?
Could Retatrutide Become a Major Obesity Treatment?
It certainly has the potential.
The Phase 3 results are encouraging, particularly the degree of weight loss seen at the highest dose.
But several questions remain.
Researchers still need longer-term information about:
- Safety
- Tolerability
- Cardiovascular outcomes
- Weight maintenance
- Real-world effectiveness
- Appropriate patient selection
- Regulatory approval
- Cost and access
Until those questions are answered, retatrutide should be viewed as a promising investigational treatment rather than an available replacement for approved medicines.
What Does Retatrutide Mean for the Future of Weight Loss?
Retatrutide shows how rapidly obesity treatment is evolving.
The field is moving beyond single-hormone approaches toward medicines that influence several biological pathways.
If future research confirms the Phase 3 findings and regulators approve the treatment, retatrutide could become an important option for people who need substantial weight reduction.
For now, however, the evidence is promising rather than final.
Frequently Asked Questions
What is retatrutide?
Retatrutide is an investigational once-weekly injectable medicine designed to activate GLP-1, GIP and glucagon receptors.
How much weight did people lose with retatrutide?
In the Phase 3 TRIUMPH-1 trial, the 12 mg group lost an average of 28.3% of body weight after 80 weeks.
Is retatrutide FDA approved?
No. Retatrutide remains investigational and is not an FDA-approved weight-loss medication.
Is retatrutide available by prescription?
It is not available as an FDA-approved prescription treatment for obesity.
Is retatrutide the same as Wegovy?
No. Wegovy contains semaglutide, while retatrutide is an investigational triple-receptor agonist.
What are the common side effects of retatrutide?
The most frequently reported adverse events include nausea, diarrhea, constipation and vomiting.
Final Takeaway
Retatrutide is one of the most closely watched developments in obesity medicine in 2026.
The Phase 3 TRIUMPH-1 results showed average weight loss of 28.3% at 80 weeks with the 12 mg dose, with even greater average loss reported in the 104-week extension among selected participants with BMI of at least 35.
Those results are impressive.
But retatrutide remains investigational.
The next stage is to determine whether its remarkable weight-loss results translate into a safe, durable and accessible treatment for people living with obesity.
Medical note: This article is for educational purposes only. Retatrutide is investigational and should not be purchased or used outside legitimate clinical research or approved medical treatment.
References
- Eli Lilly — TRIUMPH-1 Phase 3 retatrutide results, May 21, 2026.
- FDA — Information concerning unapproved GLP-1 drugs and retatrutide.
- FDA — Warning information concerning unapproved retatrutide products.
Written by Ravi Tiku
Publisher & Author | 38 Years of Pharmaceutical Sales Experience
[Medical information note: This article is for general educational purposes and is not a substitute for professional medical advice.]